Cargando…

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo

Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere...

Descripción completa

Detalles Bibliográficos
Autores principales: Mester, Simone, Evers, Mitchell, Meyer, Saskia, Nilsen, Jeannette, Greiff, Victor, Sandlie, Inger, Leusen, Jeanette, Andersen, Jan Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954421/
https://www.ncbi.nlm.nih.gov/pubmed/33691596
http://dx.doi.org/10.1080/19420862.2021.1893888
_version_ 1783664075813683200
author Mester, Simone
Evers, Mitchell
Meyer, Saskia
Nilsen, Jeannette
Greiff, Victor
Sandlie, Inger
Leusen, Jeanette
Andersen, Jan Terje
author_facet Mester, Simone
Evers, Mitchell
Meyer, Saskia
Nilsen, Jeannette
Greiff, Victor
Sandlie, Inger
Leusen, Jeanette
Andersen, Jan Terje
author_sort Mester, Simone
collection PubMed
description Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere with pH-dependent binding of albumin to the human neonatal Fc receptor (FcRn), as FcRn acts as the principal regulator of the half-life of albumin. Thus, there is a need to know how ABDs act in the context of fusion partners and human FcRn. Here, we studied the binding and transport properties of human immunoglobulin A1 (IgA1), fused to a Streptococcus protein G-derived engineered ABD, in in vitro and in vivo systems harboring human FcRn. IgA has great potential as a therapeutic protein, but its short half-life is a major drawback. We demonstrate that ABD-fused IgA1 binds human FcRn pH-dependently and is rescued from cellular degradation in a receptor-specific manner in the presence of albumin. This occurs when ABD is fused to either the light or the heavy chain. In human FcRn transgenic mice, IgA1-ABD in complex with human albumin, gave 4-6-fold extended half-life compared to unmodified IgA1, where the light chain fusion showed the longest half-life. When the heavy chain-fused protein was pre-incubated with an engineered human albumin with improved FcRn binding, cellular rescue and half-life was further enhanced. Our study reveals how an ABD, which does not interfere with albumin binding to human FcRn, may be used to extend the half-life of IgA. Abbreviations: ABD - Albumin binding domain, ADA – anti-drug-antibodies, ADCC - Antibody-dependent cellular cytotoxicity, ELISA - Enzyme-linked Immunosorbent assay, FcαRI - Fcα receptor, FcγR - Fcγ receptor, FcRn - The neonatal Fc receptor, GST - Glutathione S-transferase, HC - Heavy chain, HERA - Human endothelial cell-based recycling assay, Her2 - Human epidermal growth factor 2, HMEC - Human microvascular endothelial cells, IgG - Immunoglobulin G, IgA - Immunoglobulin A, LC - Light chain, QMP - E505Q/T527M/K573P, WT - Wild type
format Online
Article
Text
id pubmed-7954421
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-79544212021-03-23 Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo Mester, Simone Evers, Mitchell Meyer, Saskia Nilsen, Jeannette Greiff, Victor Sandlie, Inger Leusen, Jeanette Andersen, Jan Terje MAbs Report Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere with pH-dependent binding of albumin to the human neonatal Fc receptor (FcRn), as FcRn acts as the principal regulator of the half-life of albumin. Thus, there is a need to know how ABDs act in the context of fusion partners and human FcRn. Here, we studied the binding and transport properties of human immunoglobulin A1 (IgA1), fused to a Streptococcus protein G-derived engineered ABD, in in vitro and in vivo systems harboring human FcRn. IgA has great potential as a therapeutic protein, but its short half-life is a major drawback. We demonstrate that ABD-fused IgA1 binds human FcRn pH-dependently and is rescued from cellular degradation in a receptor-specific manner in the presence of albumin. This occurs when ABD is fused to either the light or the heavy chain. In human FcRn transgenic mice, IgA1-ABD in complex with human albumin, gave 4-6-fold extended half-life compared to unmodified IgA1, where the light chain fusion showed the longest half-life. When the heavy chain-fused protein was pre-incubated with an engineered human albumin with improved FcRn binding, cellular rescue and half-life was further enhanced. Our study reveals how an ABD, which does not interfere with albumin binding to human FcRn, may be used to extend the half-life of IgA. Abbreviations: ABD - Albumin binding domain, ADA – anti-drug-antibodies, ADCC - Antibody-dependent cellular cytotoxicity, ELISA - Enzyme-linked Immunosorbent assay, FcαRI - Fcα receptor, FcγR - Fcγ receptor, FcRn - The neonatal Fc receptor, GST - Glutathione S-transferase, HC - Heavy chain, HERA - Human endothelial cell-based recycling assay, Her2 - Human epidermal growth factor 2, HMEC - Human microvascular endothelial cells, IgG - Immunoglobulin G, IgA - Immunoglobulin A, LC - Light chain, QMP - E505Q/T527M/K573P, WT - Wild type Taylor & Francis 2021-03-10 /pmc/articles/PMC7954421/ /pubmed/33691596 http://dx.doi.org/10.1080/19420862.2021.1893888 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Mester, Simone
Evers, Mitchell
Meyer, Saskia
Nilsen, Jeannette
Greiff, Victor
Sandlie, Inger
Leusen, Jeanette
Andersen, Jan Terje
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
title Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
title_full Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
title_fullStr Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
title_full_unstemmed Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
title_short Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
title_sort extended plasma half-life of albumin-binding domain fused human iga upon ph-dependent albumin engagement of human fcrn in vitro and in vivo
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954421/
https://www.ncbi.nlm.nih.gov/pubmed/33691596
http://dx.doi.org/10.1080/19420862.2021.1893888
work_keys_str_mv AT mestersimone extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT eversmitchell extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT meyersaskia extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT nilsenjeannette extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT greiffvictor extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT sandlieinger extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT leusenjeanette extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo
AT andersenjanterje extendedplasmahalflifeofalbuminbindingdomainfusedhumanigauponphdependentalbuminengagementofhumanfcrninvitroandinvivo